Literature DB >> 18167063

Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis.

Go Anegawa1, Hirofumi Kawanaka, Daisuke Yoshida, Kozo Konishi, Shohei Yamaguchi, Nao Kinjo, Akinobu Taketomi, Makoto Hashizume, Hiroaki Shimokawa, Yoshihiko Maehara.   

Abstract

In liver cirrhosis, down-regulation of endothelial nitric oxide synthase (eNOS) has been implicated as a cause of increased intrahepatic resistance. We investigated whether Rho-kinase activation is one of the molecular mechanisms involved in defective eNOS signaling in secondary biliary cirrhosis. Liver cirrhosis was induced by bile duct ligation (BDL). We measured mean arterial pressure (MAP), portal venous pressure (PVP), and hepatic tissue blood flow (HTBF) during intravenous infusion of saline (control), 0.3, 1, or 2 mg/kg/hour fasudil for 60 minutes. In BDL rats, 1 and 2 mg/kg/hour fasudil significantly reduced PVP by 20% compared with controls but had no effect on HTBF. MAP was significantly reduced in response to 2 mg/kg/hour fasudil. In the livers of BDL rats, 1 and 2 mg/kg/hour fasudil significantly suppressed Rho-kinase activity and significantly increased eNOS phosphorylation, compared with controls. Fasudil significantly reduced the binding of serine/threonine Akt/PKB (Akt) to Rho-kinase and increased the binding of Akt to eNOS. These results show in secondary biliary cirrhosis that (1) Rho-kinase activation with resultant eNOS down-regulation is substantially involved in the pathogenesis of portal hypertension and (2) Rho-kinase might interact with Akt and subsequently inhibit the binding of Akt to eNOS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18167063     DOI: 10.1002/hep.22089

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

1.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 2.  Current concepts on the role of nitric oxide in portal hypertension.

Authors:  Liang Shuo Hu; Jacob George; Jian Hua Wang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

3.  Roles of vascular endothelial growth factor and endothelial nitric oxide synthase during revascularization and regeneration after partial hepatectomy in a rat model.

Authors:  Daisuke Yoshida; Tomohiko Akahoshi; Hirofumi Kawanaka; Shohei Yamaguchi; Nao Kinjo; Akinobu Taketomi; Morimasa Tomikawa; Ken Shirabe; Yoshihiko Maehara; Makoto Hashizume
Journal:  Surg Today       Date:  2011-10-04       Impact factor: 2.549

4.  Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.

Authors:  Maiko Namba; Tomokazu Kawaoka; Hiroshi Aikata; Kenichiro Kodama; Shinsuke Uchikawa; Kazuki Ohya; Kei Morio; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yasutaka Baba; Kazuo Awai; Kazuaki Chayama
Journal:  Clin J Gastroenterol       Date:  2019-01-31

5.  Autophagy enhances hepatocellular carcinoma progression by activation of mitochondrial β-oxidation.

Authors:  Takeo Toshima; Ken Shirabe; Yoshihiro Matsumoto; Shohei Yoshiya; Toru Ikegami; Tomoharu Yoshizumi; Yuji Soejima; Tetsuo Ikeda; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2013-05-24       Impact factor: 7.527

6.  Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.

Authors:  M Hennenberg; J Trebicka; C Stark; A Z Kohistani; J Heller; T Sauerbruch
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

7.  Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.

Authors:  X Wang; D Zuo; Y Chen; W Li; R Liu; Y He; L Ren; L Zhou; T Deng; X Wang; G Ying; Y Ba
Journal:  Br J Cancer       Date:  2014-10-16       Impact factor: 7.640

8.  Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.

Authors:  Cheng-Gang Zhang; Bin Zhang; Wen-Sheng Deng; Ming Duan; Wei Chen; Zhi-Yong Wu
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

9.  Strain of experimental animals and modulation of nitric oxide pathway: their influence on development of renal failure in an experimental model of hepatorenal syndrome.

Authors:  Marek Saracyn; Janusz Patera; Janusz Kocik; Marek Brytan; Robert Zdanowski; Arkadiusz Lubas; Wojciech Kozłowski; Zofia Wańkowicz
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

10.  Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study.

Authors:  Lai Wei; Juan Yang; Min Wang; Sheng-Nan Xu; Hua-Min Liang; Qi Zhou
Journal:  Int J Mol Med       Date:  2014-08-19       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.